Company Overview and News

17
Office REITs: Jobs, Jobs, Jobs

2018-06-05 seekingalpha
Despite a record 92 consecutive months of job growth, office REITs have yet to fully recover from the previous recession. The sector has been a perennial underperformer since 2007.
DEI EQC EQC.PRD EQCO PGRE BXP.PRB BXP ESRT

14
Rafael Holdings: Attractive Spin-Off Opportunity

2018-06-04 seekingalpha
Recent spin-off of IDT largely comprised of real estate and a stake in a late-stage oncology pharmaceutical venture.
ARMO IDIX SURF RFL DTK BXP.PRB BXP LLY RFL.WI

13
Boston Properties: Development Activities Will Drive Future NOI Growth

2018-06-04 seekingalpha
The company has an active development pipeline that should contribute to its NOI significantly starting in 2019.
BXP.PRB BXP

244
You Say 'Vornado', I Say 'Vornado'

2018-05-31 seekingalpha
Maybe it’s a southern thing, because when I’m in Manhattan, my fellow analysts pronounce it Vor-nah-to.
WFCNP MS.PRE WFC.PRL UE.WI MS.PRF BXP WFC.PRJ MS.PRG MS.PRA STWD.WI BAC WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO UBS WFC.PRN UBS.PRDCL MS WFC.PRY WFC.PRX WFC.PRW AB WFC.PRV WFC WFC.WS C UE MS.PRI JBGS MS.PRK BXP.PRB MSFT STWD SLG ULSGF ESRT

12
BXP / Boston Properties, Inc. 8-K (Current Report)

2018-05-29 sec.gov
Document UNITED STATES
BXP

12
BXP / Boston Properties, Inc. 8-K (Current Report)

2018-05-29 sec.gov
Document UNITED STATES
BXP

28
High-Quality REIT Yielding 6% Is Off To A Strong Start, 35% Upside Potential

2018-05-19 seekingalpha
Ventas is one of our strongest picks among REITs because it is what we consider to be a blue-chip company with a low risk profile.
VTR PSA.PRA PSA.PRB O.PRF PSA.PRY O PSA.PRZ PSA.PRW BXP OPRF PSA.PRX PSA.A PSA.PRU PSA.PRV PSA PSA.PRS PSA.PRT BXP.PRB PSAXZ PSA.PRG PSA.PRE PSA.PRF PSA.PRC PSA.PRD

14
This Strong Buy REIT Is Just What The Doctor Ordered

2018-05-15 seekingalpha
I picked these STRONG BUY names because I believe they will eventually outperform and deliver satisfying returns.
EPR.PRG JCAP BXP.PRB BXP JCAP.PRB

109
Top Research Reports for Schwab, NextEra & MetLife

2018-05-10 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Schwab (SCHW), NextEra (NEE) and MetLife (MET). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
APC TXN UNP MET BXP HSIC NEE.PRI BRK.A NEE.PRJ TSNU WPZ GM.WS.A NEE.PRC GM.WS.B GM.WS.C NEE.PRQ NEE.PRR BXP.PRB GM GM.WSB AEUA TSN NEE

12
BXP / Boston Properties, Inc. 10-Q (Quarterly Report)

2018-05-08 sec.gov
Document Table of Content
BXP

12
BXP / Boston Properties, Inc. 10-Q (Quarterly Report)

2018-05-08 sec.gov
Document Table of Content
BXP

56
Boston Properties' (BXP) CEO Owen Thomas on Q1 2018 Results - Earnings Call Transcript

2018-04-25 seekingalpha
Good morning and welcome to Boston Properties First Quarter Earnings Call. This call is being recorded. All audience lines are currently in a listen-only mode. Our speakers will address your questions at the end of the presentation during the question-and-answer session.
WFCNP STT.PRC STT.PRE STT.PRD STT.PRG WFC.PRL BXP WFC.PRJ FNMA WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO GM.WS.A WFC.PRN GM.WS.B GM.WS.C WFC.PRY GM WFC.PRX WFC.PRW WFC.PRV WFC WFC.WS STT BXP.PRB GM.WSB

37
Boston Properties (BXP) Q1 FFO Meets Estimates, Revenues Up

2018-04-25 zacks
Boston Properties Inc.’s (BXP - Free Report) first-quarter 2018 funds from operations (FFO) per share of $1.49 was in line with the Zacks Consensus Estimate. The figure was also higher than the year-ago quarter’s tally of $1.48. In addition, quarterly FFO per share was within the company’s previously guided range of $1.47-$1.49. Adjusted revenues, comprising base rent and recoveries from tenants during the quarter, increased 3.
REG ARE REG.PRG HCN REG.PRF WELL.PRI DVN BXP HCN.PRJ HCN.PRI FNMA ARE.PRD WELL BXP.PRB ARE.PRE

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

21h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 101121101